Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CEA Kit CLIA

CEA Reactivité: Humain Chemiluminescent Sandwich ELISA
N° du produit ABIN504801
  • Antigène Voir toutes CEA Kits CLIA
    CEA (Carcinoembryonic Antigen Gene Family (CEA))
    Reactivité
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain
    Méthode de détection
    Chemiluminescent
    Type de méthode
    Sandwich ELISA
    Application
    ELISA
    Fonction
    Carcinoembryonic antigen (CEA) is comprised of a heterogeneous family of glycoproteins with a molecular weight ranging from 175 to 200 k0202D due to variations in its carbohydrate and amino acid content. CEA is the first of the so-called carcinoembryonic proteins that was discovered in 1965 by Gold and Freeman (1). Even though its biological function is not very well defined CEA is the most widely used marker for colo-rectal cancer. Although CEA is primarily associated with colorectal cancers (CRC), other malignancies that can cause elevated levels of CEA include breast, lung, stomach, pancreas, ovary and other organs. Benign conditions that cause significantly higher than normal levels include inflammation of lung and gastrointestinal (GI) tract and benign liver cancer (2, 3). Heavy Smokers, as a group, have higher than normal baseline concentration of CEA. Serum values in healthy adults are normally < 5.0 ng/ml however, serum values exceeding 5 times the normal reference range are taken as indicative of malignancy. Also, values seen in malignant and non-malignant conditions can overlap thus making CEA a not very dependable marker for malignancy. However, the real use of CEA lies in its importance in patient prognosis, status assessment and monitoring. In addition, monitoring CEA levels during chemotherapy before surgery can be informative, and the failure of CEA to fall during pre-operative radiotherapy usually indicates the presence of a tumor outside the field of radiation and a poor prognosis. Levels have been seen to drop to normal in 4-6 weeks after a successful resection of CRC. In this method, CEA calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different epitopes of CEA) are added and the reactants mixed. Reaction between the various CEA antibodies and native CEA forms a sandwich complex that binds with the streptavidin coated to the well. After the completion of the required incubation period, the enzyme-CEA antibody bound conjugate is separated from the unbound enzyme-CEA conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce light. The employment of several serum references of known carcinoembryonic antigen (CEA) levels permits the construction of a dose response curve of activity and con_x001F_centration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with CEA concentration.
    Analytical Method
    Quantitative
    Attributs du produit
    The Quantitative Determination of Carcinoembryonic Antigen (CEA) Concentration in Human Serum by a Microplate Chemiluminescence assay (For Research Use Only)
    Featured
    Discover our best selling CEA Kit ELISA
    Top Product
    Discover our top product CEA Kit ELISA
  • Indications d'application
    All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.
    Volume d'échantillon
    25 μL
    Plaque
    Pre-coated
    Protocole

    Specimien Collection and Preparation:

    The specimens shall be blood, serum in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants. Allow the blood to clot. Centrifuge the specimen to separate the serum from the cells. Samples may be refrigerated at 2_x001E_8C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of _x001E_20C for up to 30 days. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml of the specimen is required.

    Reagent Preparation:

    1. Wash Buffer Dilute contents of Wash Concentrate to 1000ml with distilled or deionized water in a suitable storage container. Store at room temperature (20-27(C) for up to 60 days. 2. Working Signal Reagent Solution - Store at 2 - 8(C. Determine the amount of reagent needed and prepare by mixing equal portions of Signal Reagent A and Signal Reagent B in a clean container. For example, add 1 ml of A and 1ml of B per two (2) eight well strips (A slight excess of solution is made). Discard the unused portion if not used within 36 hours after mixing. If complete utilization of the reagents is anticipated, within the above time constraint, pour the contents of Signal Reagent B into Signal Reagent A and label accordingly. .

    Test Procedure:

    Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20 - 27(C). 1. Format the microplates wells for each serum reference, control and patient specimen to be assayed in duplicate. Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8(C. 2. Pipette 0.025 ml (25l) of the appropriate serum reference, control or specimen into the assigned well. 3. Add 0.100 ml (100l) of the CEA Tracer Reagent to each well. It is very important to dispense all reagents close to the bottom of the coated well. 4. Swirl the microplate gently for 20-30 seconds to mix and cover. 5. Incubate 45 minutes at room temperature. 6. Discard the contents of the microplate by decantation or aspiration. If decanting, tap and blot the plate dry with absorbent paper. 7. Add 350l of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat four (4) additional times for a total of five (5) washes. An automatic or manual plate washer can be used. Follow the manufacturers instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat four (4) additional times. Add 0.100 ml (100l) of working signal reagent to all wells (see Reagent Preparation Section). ). Always add reagents in the same order to minimize reaction time differences between wells. Incubate for five (5) minutes in the dark. 10. Read the relative light units in each well for 0.2 1.0 seconds. The results should be read within thirty (30) minutes of adding the substrate solution.
    Restrictions
    For Research Use only
  • Antigène Voir toutes CEA Kits CLIA
    CEA (Carcinoembryonic Antigen Gene Family (CEA))
    Autre désignation
    Carcinoembryonic Antigen (CEA) (CEA Produits)
    Synonymes
    RGD1311281 Kit CLIA, carcinoembryonic antigen-related cell adhesion molecule 20 Kit CLIA, carcinoembryonic antigen gene family Kit CLIA, Ceacam20 Kit CLIA, Cea Kit CLIA
    Sujet
    Carcinoembryonic antigen (CEA) is comprised of a heterogeneous family of glycoproteins with a molecular weight ranging from 175 to 200 k0202D due to variations in its carbohydrate and amino acid content. CEA is the first of the so-called carcinoembryonic proteins that was discovered in 1965 by Gold and Freeman (1). Even though its biological function is not very well defined CEA is the most widely used marker for colo-rectal cancer. Although CEA is primarily associated with colorectal cancers (CRC), other malignancies that can cause elevated levels of CEA include breast, lung, stomach, pancreas, ovary and other organs. Benign conditions that cause significantly higher than normal levels include inflammation of lung and gastrointestinal (GI) tract and benign liver cancer (2, 3). Heavy Smokers, as a group, have higher than normal baseline concentration of CEA. Serum values in healthy adults are normally < 5.0 ng/ml however, serum values exceeding 5 times the normal reference range are taken as indicative of malignancy. Also, values seen in malignant and non-malignant conditions can overlap thus making CEA a not very dependable marker for malignancy. However, the real use of CEA lies in its importance in patient prognosis, status assessment and monitoring. In addition, monitoring CEA levels during chemotherapy before surgery can be informative, and the failure of CEA to fall during pre-operative radiotherapy usually indicates the presence of a tumor outside the field of radiation and a poor prognosis. Levels have been seen to drop to normal in 4-6 weeks after a successful resection of CRC. In this method, CEA calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different epitopes of CEA) are added and the reactants mixed. Reaction between the various CEA antibodies and native CEA forms a sandwich complex that binds with the streptavidin coated to the well. After the completion of the required incubation period, the enzyme-CEA antibody bound conjugate is separated from the unbound enzyme-CEA conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce light. The employment of several serum references of known carcinoembryonic antigen (CEA) levels permits the construction of a dose response curve of activity and con_x001F_centration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with CEA concentration.
Vous êtes ici:
Support technique